Biotech Values

[DewDiligence]

SGP – Chalk one up for Fred Hassan and deduct another point from PFE’s score for abandoning this program. In the 2007 CC announcing SGP’s acquisition of Organon, Hassan assured disbelieving analysts that asenipine would prove to be an important drug.

If I recall correctly, this is one that ‘neuroinv’ got wrong, so at least PFE was in good company :- )